Results of a database review revealed duloxetine, pregabalin, and milnacipran as the only effective pharmacological therapies for managing pain in fibromyalgia.
Tofacitinib and TNF inhibitors demonstrated similar efficacy for managing RA at 12 months, with minor differences noted across tofacitinib treatment lines.
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
Initiating methotrexate within 2 years of a psoriasis diagnosis is associated with a reduced risk of progressing to PsA.
Pediatric exposures to caffeine energy products increased from 2011 to 2023, although most exposures had minimal clinical effects.
The FDA has accepted for Priority Review the NDA for vatiquinone for the treatment of children and adults living with Friedreich ataxia.
From 2008 to 2017, there was an increase in the prevalence of being free of all disabilities among the US population aged 65 years or older.
Higher leptin levels were associated with chronic widespread pain among patients with RA, even after adjusting for age, BMI, and sex.
The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.
Pediatric patients who adopted and sustained a CD exclusion diet achieved clinical remission and reported improvement in clinical symptoms and fecal calprotectin.
Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.
Adherence to a healthier, anti-inflammatory diet was associated with a reduced risk for all-cause mortality among patients with RA.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results